Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & Administrative
Others
Ratios

NewAmsterdam Pharma (NAMS) EBITDA (2023 - 2025)

Historic EBITDA for NewAmsterdam Pharma (NAMS) over the last 3 years, with Q3 2025 value amounting to -$71.7 million.

  • NewAmsterdam Pharma's EBITDA fell 33066.02% to -$71.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$220.9 million, marking a year-over-year decrease of 1102.93%. This contributed to the annual value of -$241.6 million for FY2024, which is 3651.92% down from last year.
  • NewAmsterdam Pharma's EBITDA amounted to -$71.7 million in Q3 2025, which was down 33066.02% from -$17.5 million recorded in Q2 2025.
  • In the past 5 years, NewAmsterdam Pharma's EBITDA ranged from a high of -$16.6 million in Q3 2024 and a low of -$93.8 million during Q1 2024
  • Moreover, its 3-year median value for EBITDA was -$42.0 million (2023), whereas its average is -$49.7 million.
  • As far as peak fluctuations go, NewAmsterdam Pharma's EBITDA skyrocketed by 6468.08% in 2024, and later tumbled by 33066.02% in 2025.
  • NewAmsterdam Pharma's EBITDA (Quarter) stood at -$49.5 million in 2023, then plummeted by 86.14% to -$92.1 million in 2024, then grew by 22.19% to -$71.7 million in 2025.
  • Its EBITDA was -$71.7 million in Q3 2025, compared to -$17.5 million in Q2 2025 and -$39.6 million in Q1 2025.